Literature DB >> 20825274

Series: The research agenda for general practice/family medicine and primary health care in Europe. Part 4. Results: specific problem solving skills.

Eva Hummers-Pradier1, Martin Beyer, Patrick Chevallier, Sophia Eilat-Tsanani, Christos Lionis, Lieve Peremans, Davorina Petek, Imre Rurik, Jean Karl Soler, Henri Ejh Stoffers, Pinar Topsever, Mehmet Ungan, Paul van Royen.   

Abstract

The 'Research Agenda for General Practice/Family Medicine and Primary Health Care in Europe' summarizes the evidence relating to the core competencies and characteristics of the Wonca Europe definition of GP/FM, and its implications for general practitioners/family doctors, researchers and policy makers. The European Journal of General Practice publishes a series of articles based on this document. The previous articles presented background, objectives, and methodology, as well results on 'primary care management' and 'community orientation' and the person-related core competencies of GP/FM. This article reflects on the general practitioner's 'specific problem solving skills'. These include decision making on diagnosis and therapy of specific diseases, accounting for the properties of primary care, but also research questions related to quality management and resource use, shared decision making, or professional education and development. Clinical research covers most specific diseases, but often lacks pragmatism and primary care relevance. Quality management is a stronghold of GP/FM research. Educational interventions can be effective when well designed for a specific setting and situation. However, their message that 'usual care' by general practitioners is insufficient may be problematic. GP and their patients need more research into diagnostic reasoning with a step-wise approach to increase predictive values in a setting characterized by uncertainty and low prevalence of specific diseases. Pragmatic comparative effectiveness studies of new and established drugs or non-pharmaceutical therapy are needed. Multi-morbidity and complexity should be addressed. Studies on therapy, communication strategies and educational interventions should consider impact on health and sustainability of effects.

Entities:  

Mesh:

Year:  2010        PMID: 20825274     DOI: 10.3109/13814788.2010.504982

Source DB:  PubMed          Journal:  Eur J Gen Pract        ISSN: 1381-4788            Impact factor:   1.904


  10 in total

1.  Practices, patients and (im)perfect data--feasibility of a randomised controlled clinical drug trial in German general practices.

Authors:  Ildikó Gágyor; Jutta Bleidorn; Karl Wegscheider; Eva Hummers-Pradier; Michael M Kochen
Journal:  Trials       Date:  2011-04-01       Impact factor: 2.279

2.  What research agenda could be generated from the European General Practice Research Network concept of Multimorbidity in Family Practice?

Authors:  J Y Le Reste; P Nabbe; H Lingner; D Kasuba Lazic; R Assenova; M Munoz; A Sowinska; C Lygidakis; C Doerr; S Czachowski; S Argyriadou; J Valderas; B Le Floch; J Deriennic; T Jan; E Melot; P Barraine; M Odorico; C Lietard; P Van Royen; H Van Marwijk
Journal:  BMC Fam Pract       Date:  2015-09-17       Impact factor: 2.497

3.  The European general practice research network presents the translations of its comprehensive definition of multimorbidity in family medicine in ten European languages.

Authors:  Jean Yves Le Reste; Patrice Nabbe; Charles Rivet; Charilaos Lygidakis; Christa Doerr; Slawomir Czachowski; Heidrun Lingner; Stella Argyriadou; Djurdjica Lazic; Radost Assenova; Melida Hasaganic; Miquel Angel Munoz; Hans Thulesius; Bernard Le Floch; Jeremy Derriennic; Agnieska Sowinska; Harm Van Marwijk; Claire Lietard; Paul Van Royen
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

4.  Reliability and validity of the script concordance test for postgraduate students of general practice.

Authors:  Julie Subra; Bruno Chicoulaa; André Stillmunkès; Pierre Mesthé; Stéphane Oustric; Marie-Eve Rougé Bugat
Journal:  Eur J Gen Pract       Date:  2017-12       Impact factor: 1.904

5.  Multimorbid outpatients: A high frequency of FP appointments and/or family difficulties, should alert FPs to the possibility of death or acute hospitalization occurring within six months; A primary care feasibility study.

Authors:  Jean Yves Le Reste; Patrice Nabbe; Alice Billot Grasset; Bernard Le Floch; Pauline Grall; Jeremy Derriennic; Michele Odorico; Sophie Lalande; Delphine le Goff; Marie Barais; Benoit Chiron; Heidrun Lingner; Morgane Guillou; Pierre Barraine
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

6.  Research agenda in family medicine-should we adopt the Dutch approach?

Authors:  Shlomo Vinker; Mehmet Ungan
Journal:  Eur J Gen Pract       Date:  2019-02-05       Impact factor: 1.904

Review 7.  General practice-based clinical trials in Germany - a problem analysis.

Authors:  Eva Hummers-Pradier; Jutta Bleidorn; Guido Schmiemann; Stefanie Joos; Annette Becker; Attila Altiner; Jean-François Chenot; Martin Scherer
Journal:  Trials       Date:  2012-11-08       Impact factor: 2.279

8.  Clinical drug trials in general practice: a 10-year overview of protocols.

Authors:  Anja Maria Brænd; Kaspar Buus Jensen; Atle Klovning; Jørund Straand
Journal:  Trials       Date:  2013-06-01       Impact factor: 2.279

9.  Different Multimorbidity Measures Result in Varying Estimated Levels of Physical Quality of Life in Individuals with Multimorbidity: A Cross-Sectional Study in the General Population.

Authors:  Aline Ramond-Roquin; Jeannie Haggerty; Mireille Lambert; Jose Almirall; Martin Fortin
Journal:  Biomed Res Int       Date:  2016-03-16       Impact factor: 3.411

Review 10.  Which positive factors determine the GP satisfaction in clinical practice? A systematic literature review.

Authors:  B Le Floch; H Bastiaens; J Y Le Reste; H Lingner; R D Hoffman; S Czachowski; R Assenova; T H Koskela; Z Klemenc-Ketis; P Nabbe; A Sowinska; T Montier; L Peremans
Journal:  BMC Fam Pract       Date:  2016-09-13       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.